FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.
CMS Launches National Coverage Analysis, Citing FDA’s Black Box Warning on ESAs.
FDA Purges Quality of Life Claims from Oncology Label for ESAs.
Amgen Says It Can Demonstrate Safety of Existing Hg Target.
If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting.
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget
- NIH calls for comment on proposal to limit the number of RPGs per PI
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe









